These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19884330)

  • 1. Discordant Brucella melitensis antigens yield cognate CD8+ T cells in vivo.
    Durward MA; Harms J; Magnani DM; Eskra L; Splitter GA
    Infect Immun; 2010 Jan; 78(1):168-76. PubMed ID: 19884330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice.
    Vitry MA; De Trez C; Goriely S; Dumoutier L; Akira S; Ryffel B; Carlier Y; Letesson JJ; Muraille E
    Infect Immun; 2012 Dec; 80(12):4271-80. PubMed ID: 23006848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
    Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H
    Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal vaccination stimulates CD8(+) T cells for potent protection against mucosal Brucella melitensis challenge.
    Clapp B; Yang X; Thornburg T; Walters N; Pascual DW
    Immunol Cell Biol; 2016 May; 94(5):496-508. PubMed ID: 26752510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8+ T cell exhaustion, suppressed gamma interferon production, and delayed memory response induced by chronic Brucella melitensis infection.
    Durward-Diioia M; Harms J; Khan M; Hall C; Smith JA; Splitter GA
    Infect Immun; 2015 Dec; 83(12):4759-71. PubMed ID: 26416901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.
    Cassataro J; Velikovsky CA; de la Barrera S; Estein SM; Bruno L; Bowden R; Pasquevich KA; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Oct; 73(10):6537-46. PubMed ID: 16177328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection.
    Sadeghi Z; Fasihi-Ramandi M; Bouzari S
    Int Immunopharmacol; 2019 Oct; 75():105829. PubMed ID: 31437796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
    Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of Brucella abortus recombinant protein cocktail (rOmp19+rP39) against B. abortus 544 and B. melitensis 16M infection in murine model.
    Tadepalli G; Singh AK; Balakrishna K; Murali HS; Batra HV
    Mol Immunol; 2016 Mar; 71():34-41. PubMed ID: 26826463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
    Al-Mariri A; Abbady AQ
    J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis.
    Vitry MA; Hanot Mambres D; De Trez C; Akira S; Ryffel B; Letesson JJ; Muraille E
    J Immunol; 2014 Apr; 192(8):3740-52. PubMed ID: 24646742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brucella melitensis T cell epitope recognition in humans with brucellosis in Peru.
    Cannella AP; Arlehamn CS; Sidney J; Patra KP; Torres K; Tsolis RM; Liang L; Felgner PL; Saito M; Gotuzzo E; Gilman RH; Sette A; Vinetz JM
    Infect Immun; 2014 Jan; 82(1):124-31. PubMed ID: 24126518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
    Cloeckaert A; Jacques I; Grilló MJ; Marín CM; Grayon M; Blasco JM; Verger JM
    Vaccine; 2004 Jul; 22(21-22):2827-35. PubMed ID: 15246618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immunogenicity of OMP31 Peptides and Its Protection Against Brucella melitensis Infection in Mice.
    Zhang F; Li Z; Jia B; Zhu Y; Pang P; Zhang C; Ding J
    Sci Rep; 2019 Mar; 9(1):3512. PubMed ID: 30837598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
    Mailybayeva A; Yespembetov B; Ryskeldinova S; Zinina N; Sansyzbay A; Renukaradhya GJ; Petrovsky N; Tabynov K
    PLoS One; 2017; 12(10):e0186484. PubMed ID: 29023541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.
    Al-Mariri A
    Vaccine; 2010 Feb; 28(7):1766-70. PubMed ID: 20036752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo immunogenicity assessment and vaccine efficacy evaluation of a chimeric tandem repeat of epitopic region of OMP31 antigen fused to interleukin 2 (IL-2) against Brucella melitensis in BALB/c mice.
    Nazifi N; Tahmoorespur M; Sekhavati MH; Haghparast A; Behroozikhah AM
    BMC Vet Res; 2019 Nov; 15(1):402. PubMed ID: 31703683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel recombinant multi-epitope protein against Brucella melitensis infection.
    Yin D; Li L; Song D; Liu Y; Ju W; Song X; Wang J; Pang B; Xu K; Li J
    Immunol Lett; 2016 Jul; 175():1-7. PubMed ID: 27133932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies.
    Li J; Hu F; Chen S; Luo P; He Z; Wang W; Allain JP; Li C
    BMC Microbiol; 2017 May; 17(1):115. PubMed ID: 28506316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potential antigens from non-classically secreted proteins and designing novel multitope peptide vaccine candidate against Brucella melitensis through reverse vaccinology and immunoinformatics approach.
    Vishnu US; Sankarasubramanian J; Gunasekaran P; Rajendhran J
    Infect Genet Evol; 2017 Nov; 55():151-158. PubMed ID: 28919551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.